Global Atipamezole Market to Reach $194.27 Million by 2031 as Veterinary Sedation Reversal Demand Rises

Global Atipamezole Market to Reach $194.27 Million by 2031 as Veterinary Sedation Reversal Demand Rises Dublin, Aug. 19, 2026 (GLOBE NEWSWIRE) -- The "Atipamezole - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)" has been added to ResearchAndMarkets.com's offering.

The global atipamezole market is projected to grow from USD 126.98 million in 2025 to USD 134.75 million in 2026, reaching USD 194.27 million by 2031. The market is expected to register a compound annual growth rate of 7.59% from 2026 to 2031, supported by increasing companion animal ownership, expanding veterinary surgical volumes, and wider adoption of reversible sedation protocols.

Companion Animal Care Supports Atipamezole Market Growth

Rising demand for companion animal healthcare is strengthening the outlook for the atipamezole market. In 2025, approximately 95 million U.S. households owned pets, with dogs present in 53% of households and cats in 39%. Cat ownership also increased by 5% year over year. This expanding pet population is generating higher volumes of preventive care, diagnostic imaging, dental procedures, and elective surgeries requiring sedation.

Access to veterinary services remains an important market driver. In 2025, 83.4% of U.S. pet owners reported having a regular veterinarian, while dog owners spent an average of USD 598 on veterinary care. These trends support recurring demand for medetomidine- and dexmedetomidine-based sedation procedures and, consequently, atipamezole products used for reversal.

Veterinary Surgical Throughput Drives Adoption

Veterinary clinics and hospitals are increasingly prioritizing efficient patient recovery and optimized clinical capacity. Atipamezole supports faster recovery following eligible sedation protocols, helping veterinary teams manage cage availability, observation requirements, staff time, and daily procedure schedules. Its role in predictable post-procedural recovery is particularly valuable to high-volume urban clinics, referral hospitals, emergency facilities, and specialty veterinary centers.

Market expansion is also being supported by greater protocol standardization in small animal practices and rising demand for pre-measured veterinary drug formats. However, growth remains constrained by atipamezole's dependence on medetomidine and dexmedetomidine sedation protocols, as well as species-specific approvals, veterinary drug regulations, and labeling requirements.

Product Form and Administration Analysis

Injectable solutions accounted for 62.43% of the atipamezole market in 2025, reflecting established regulatory approvals, routine clinic stocking practices, and widespread use in veterinary care. Compounded injectable formulations are forecast to record the fastest product-form growth, advancing at an 8.42% CAGR through 2031. This expansion is associated with clearer U.S. veterinary compounding conditions following the FDA's August 2024 update to Guidance for Industry #256.

Intramuscular administration generated 65.76% of market revenue in 2025 and remained the leading route due to its established position in approved product labeling and routine veterinary anesthesia protocols. Intravenous administration is expected to post the fastest route-based CAGR of 8.45% through 2031, supported by demand in referral hospitals, critical care facilities, and acute post-anesthetic management settings.

Regional Atipamezole Market Outlook

North America held 37.45% of the global atipamezole market in 2025, making it the largest regional market. Its leadership is underpinned by advanced veterinary infrastructure, high companion animal healthcare spending, and established use of reversible sedation protocols. Europe also represents a significant market, supported by multiple authorized products and a structured veterinary regulatory environment.

Asia-Pacific is forecast to be the fastest-growing region, registering an 8.73% CAGR through 2031. Urbanization, increasing disposable income, growing pet ownership, and continued investment in private veterinary clinics are expanding formal animal healthcare services across the region. Japan represents a highly regulated premium market, while China, India, and South Korea offer substantial volume growth opportunities.

Key Topics Covered

1 Introduction

1.1 Study Assumptions & Market Definition

1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

4.1 Market Overview

4.2 Market Drivers

4.2.1 Rising Companion Animal Sedation Reversal Demand

4.2.2 Expansion of Veterinary Surgical Throughput

4.2.3 Higher Protocol Standardization in Small Animal Clinics

4.2.4 Growth in Pre-Measured Veterinary Drug Formats

4.2.5 Wider Use in Research and Laboratory Animal Protocols

4.2.6 Faster Clinic Turnaround From Rapid Recovery Agents

4.3 Market Restraints

4.3.1 Narrow Species and Indication Dependence

4.3.2 Stringent Veterinary Drug Approval and Labeling Requirements

4.3.3 Competitive Pressure From Alternative Sedation Regimens

4.3.4 Limited Awareness in Small and Mid-Tier Veterinary Practices

4.4 Supply-Chain Analysis

4.5 Regulatory Landscape

4.6 Porter's Five Forces

4.6.1 Threat of New Entrants

4.6.2 Bargaining Power of Suppliers

4.6.3 Bargaining Power of Buyers

4.6.4 Threat of Substitutes

4.6.5 Industry Rivalry

5 Market Size & Growth Forecasts (Value, USD)

5.1 By Product Form

5.1.1 Injectable Solution

5.1.2 Prefilled Syringe

5.1.3 Multi-Dose Vial

5.1.4 Compounded Injectable Formulations

5.2 By Route of Administration

5.2.1 Intramuscular

5.2.2 Intravenous

5.2.3 Subcutaneous

5.3 By Animal Type

5.3.1 Dogs

5.3.2 Cats

5.3.3 Horses

5.3.4 Exotic and Zoo Animals

5.3.5 Others (Cattle, Sheep, Goats, etc.)

5.4 By Application

5.4.1 Veterinary Sedation Reversal

5.4.2 Research and Experimental Use

5.4.3 Diagnostic and Imaging Support

5.4.4 Emergency and Post-Procedural Recovery

5.5 By End User

5.5.1 Veterinary Clinics

5.5.2 Veterinary Hospitals

5.5.3 Research Institutes

5.5.4 Other End Users

5.6 By Distribution Channel

5.6.1 Direct Sales

5.6.2 Veterinary Pharmacies

5.6.3 Online Pharmacies

5.6.4 Other Distribution Channels

5.7 By Geography

5.7.1 North America

5.7.1.1 United States

5.7.1.2 Canada

5.7.1.3 Mexico

5.7.2 Europe

5.7.2.1 Germany

5.7.2.2 United Kingdom

5.7.2.3 France

5.7.2.4 Italy

5.7.2.5 Spain

5.7.2.6 Rest of Europe

5.7.3 Asia-Pacific

5.7.3.1 China

5.7.3.2 India

5.7.3.3 Japan

5.7.3.4 Australia

5.7.3.5 South Korea

5.7.3.6 Rest of Asia-Pacific

5.7.4 Middle East and Africa

5.7.4.1 GCC

5.7.4.2 South Africa

5.7.4.3 Rest of Middle East and Africa

5.7.5 South America

5.7.5.1 Brazil

5.7.5.2 Argentina

5.7.5.3 Rest of South America

6 Competitive Landscape

6.1 Market Concentration

6.2 Market Share Analysis

6.3 Company Profiles {(includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)}

6.3.1 Bimeda Holdings plc

6.3.2 Bioveta, a.s.

6.3.3 Boehringer Ingelheim International GmbH

6.3.4 Ceva

6.3.5 Chanelle Pharma Group

6.3.6 Cronus Pharma LLC

6.3.7 Dechra Pharmaceuticals Limited

6.3.8 HIPRA S.A.

6.3.9 Huvepharma

6.3.10 Laboratorios Calier, S.A.

6.3.11 Merck Animal Health

6.3.12 Norbrook Laboratories Ltd.

6.3.13 Orion Corporation

6.3.14 Parnell Pharmaceuticals Holdings Ltd.

6.3.15 ProDivet Pharmaceuticals SA/NV

6.3.16 Vetoquinol S.A.

6.3.17 Vetpharma Animal Health, S.L.

6.3.18 Virbac

6.3.19 Zoetis Inc.

7 Market Opportunities & Future Outlook

7.1 White-space & unmet-need assessment

For more information about this report visit https://www.researchandmarkets.com/r/757za5

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.